GlassScriptPhysician profile
Ngoc-Thuy Bui
NPI 1306080361
$4,185.70
in general payments reported to CMS, 2019-2025
32 companies · $601 in 2025
The $601 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $463 · 2020: $409 · 2021: $561 · 2022: $674 · 2023: $802 · 2024: $676 · 2025: $601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,079.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,078.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $800.76 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $705.67 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $600.99 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $377.19 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Gilead Sciences, INC. | $322.15 | 2019-2025 | |
| Novo Nordisk INC | $282.95 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $134.55 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $117.24 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $92.48 | 2019-2022 | |
| Vbi Vaccine (Delaware) INC. | $68.93 | 2022 | |
| Exact Sciences Corporation | $67.41 | 2023-2025 | Cologuard Collection Kit |
| Indivior INC. | $66.98 | 2023-2025 | Sublocade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.45 | 2020-2021 | |
| Abbvie INC. | $54.96 | 2020-2024 | |
| Sanofi-Aventis U.S. LLC | $53.80 | 2019-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $52.94 | 2023-2024 | Repatha, Otezla |
| Seqirus USA INC | $46.86 | 2021-2025 | Flucelvax, Fluad |
| Dynavax Technologies Corporation | $36.95 | 2019 | |
| Janssen Pharmaceuticals, INC | $29.59 | 2021 | |
| Orexo US, INC. | $28.18 | 2019 | |
| Genentech USA, INC. | $28.04 | 2019 | |
| Alkermes, INC. | $20.60 | 2022 | |
| Inspire Medical Systems, INC. | $17.04 | 2023 | Inspire |
| Hologic Sales and Service, LLC | $16.72 | 2021 | |
| Esperion Therapeutics, INC. | $15.38 | 2021 | |
| Sanofi Pasteur INC. | $14.11 | 2024 | |
| Avion Pharmaceuticals | $13.65 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.09 | 2024 | Zoryve |
| Amarin Pharma, INC. | $12.89 | 2020 | |
| Allergan, INC. | $12.32 | 2020 | |
| Boston Scientific Corporation | $11.94 | 2021 | |
| Qiagen, LLC | $11.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ngoc-Thuy Bui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.